Convalescent Plasma for Severe Pneumonia from COVID-19

After testing multiple drugs and drug combinations in COVID-19 patients, only Remdesivir – for hospitalized patients – and dexamethasone – in patients requiring Oxygen – have shown some benefits. 

Plasma de convalecientes para neumonía severa por COVID-19

Convalescent plasma has been used for years assuming passive immunization might help control the infection until a specific immune response is established in the infected person. However, convalescent plasma has been reported effective only for one infectious disease: the Argentinian Hemorrhagic Syndrome. 

A few open, non-randomized studies have shown some promise, but with no conclusive data. 

This study randomized adult patient with severe pneumonia from COVID-19 2:1 to convalescent plasma vs. placebo. It included 228 receiving plasma vs. 105 receiving placebo. The primary end point was clinical status at 30 days measured in a 6-point scale (from total recovery to death). 


Read also: The Transradial Approach Continues to Be the Best for Primary PCI.


Mean time between symptom onset and study inclusion was 8 days (from 5 to 10 days) and hypoxemia was the most frequent severity criterion. The SARS-CoV-2 antibody titer was 1:3200. 

After 30 days there were no significant differences between the groups (OR 0.83 CI 95%, 0.52 to 1.35; p=0.46).

Total mortality was 10.96% in the group receiving plasma and 11.43% in the group receiving placebo, a non-significant difference.


Read also: Boston Scientific Discontinues Lotus Valve and Makes a New Bet.


SARS-CoV-2 antibody titers tended to be higher in the group receiving convalescent plasma 2 days after intervention. 

Both total adverse events and major events rate were similar. 

Conclusion

There were no significant differences in clinical status or total mortality between patients with severe pneumonia from COVID-19 receiving convalescent plasma vs. placebo. 

Original Title: A Randomized Trial of Convalescent Plasma in COVID-19 Severe Pneumonia. The PlasmAr Study Group.

Reference: V.A. Simonovich et al. N Engl J Med. 2020 Nov 24. Online ahead of print. doi: 10.1056/NEJMoa2031304.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...